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Introduction
Heart transplantation has been established as gold standard 
in the treatment of patients with end-stage heart failure 
(HF). It is considered after medical and resynchronisation 
therapy have failed. State-of-the-art medical therapy 
comprises treatment with betablockers, angiotensin-
converting inhibitors or angiotensin-II antagonists, and 
diuretics including aldosterone receptor antagonists (1). 
In  addi t ion to  pharmacologica l  therapy,  cardiac 
resynchronisation therapy is installed, if the preconditions 
are given (2). In patients with a moderate or higher degree 
of mitral insufficiency, the relatively new technique of 
mitral clipping is applied (3). Only after all these measure 
have not been successful in improving the degree of HF, 
heart transplantation remains the final option. Due to the 
growing number of patients with severely advanced HF 
and, at the same time, the stagnating number of available 
donor hearts, heart transplantation remains an option 
only for a limited number of those patients. Mechanical 
circulatory support with the most recent devices could 
become an alternative, since it currently achieves survival 
rates in selected patients which approach those after heart 
transplantation (4). However, reliable survival data are only 
available over the short term of a few years, in contrast to 
heart transplantation where we are able to oversee outcome 
over a period of three decades and more (5). The same is 
true for the spectrum of specific adverse events which are 
inherent to each of those therapies. It is a rather demanding 
challenge to recommend the appropriate therapy to an 
individual patient on the basis of the currently available 
outcome data. With this background in mind, the present 
article intents to review the actual outcome after heart 
transplantation with respect to survival and adverse events.
Survival of heart transplant recipients
Survival after heart transplantation is excellent, particularly if 
it is compared with the natural course of end-stage HF. The 
most recent data of the registry of the International Society 
of Heart and Lung Transplantation indicates a current 
1-year survival of 84.5% and a 5-year survival of 72.5% (5). 
This has significantly improved as compared to the 76.9% 
1-year survival and 62.7% 5-year survival in the 1980s. 
The development of new immunosuppressive drugs which 
allow a variety of immunosuppressive regimens, tailored to 
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the individual patient, has contributed to this success, since 
rejection and the adverse effects of immunosuppression could 
be better controlled. After 20 years, ca. 21% of patients are 
still alive, according to the international registry (5). In 
some experienced centers, long-term survival is reported to 
be even higher (6-9). The University Hospital Zurich has 
achieved a 20-year survival rate of 55.6% (10). 
The improvement in outcome over the decades is related 
mainly to an increase in survival over the first year. After this 
period, the attrition rate of ca. 3-4% per year has remained 
similar over the different eras. This might be attributable to 
the fact that it was not possible to reduce the incidence of 
long-term complications after heart transplantation, such 
as chronic allograft vasculopathy (CAV) and malignancies, 
which account for ca. 35% of all deaths after 10 to 15 years (5).
Complications following heart transplantation
Conditions such as CAV, malignancy, infection, acute 
rejection and renal insufficiency have a major impact on 
outcome following heart transplantation.
Chronic allograft vasculopathy (CAV)
Five years after heart transplantation, ca. one third of patients 
are diagnosed with CAV. After ten years, CAV occurs in 
more than 50% of patients. This has an important impact on 
survival. More than three years after transplantation, CAV 
accounts for ca. 10% of deaths annually (5). 
The incidence of CAV has not been changed much over the 
years, despite the availability of modern immunosuppressive 
drugs. The freedom form CAV at 5 years following heart 
transplantation only increased by 3% from 67% to 70% 
in the first decade of this century as compared the decade 
before (5).
In our own experience, CAV has been less frequently 
the cause of death as compared to other studies. Possible 
explanations for this phenomenon could be the annual 
performance of angiographies which lead to early detection 
of potentially lethal stenoses, and the routine administration 
of statins which have been shown to limit progression of 
CAV (10).
Malignancies
Currently, 15% of patients suffer from a malignancy 5 years 
after transplantation. This is only 3% less as compared to 
the previous decade in the 1990s. After 10 years, 35% of 
patients are affected by malignancies (5). The predominant 
malignancy is skin cancer. More than 5 years after 
transplantation, malignancy accounts for ca. 22% of deaths 
annually (5). As for CAV, there has been not much change 
over the decades. With specific measures, however, incidence 
and death rate might be reduced. Thus, we have reported 
that, after 10 years, the incidence of malignancies stays at 
ca. 25%, which is 10% lower as reported by the ISHLT 
(5,10). This relative success may have been achieved by the 
frequent check-ups in specialised outpatient clinics, as well as 
by the routine application of statins which we have shown to 
improve malignancy-free survival (11).
Infection
Infection constitutes a serious condition, predominantly 
within the first year after transplantation when it causes 
30% of deaths. In the following years, the death rate 
decreases to 10% annually (5). The high incidence of 
infection-related deaths within the first year might be 
explained by the higher dosage of immunosuppression 
which is required to control the more intense immune 
reponse early after transplantation. After reduction of 
immunosuppression in the following years, the risk of 
infection-related death is reduced. 
Acute rejection
Acute rejection episodes account for ca. 10% of deaths within 
the first three years after transplantation. Later, the 
incidence and impact on death decreases markedly (5). 
However, it has been shown that acute rejection triggers 
progression of CAV with all its consequences on transplant 
performance and death.
Renal insufficiency
Renal insufficiency develops as side effect of immunosuppressive 
drugs, particularly calcineurin-inhibitors such as cyclosporin 
and tacrolimus. They are given on an already impaired 
kidney function which is the result of a long-standing cardiac 
low-output syndrome. Five years after transplantation, 16% 
of patients have severe renal dysfunction which is defined 
as creatinine >2.5 mg/dL, dialysis or renal transplant. After 
10 years, 30% of patients are effected Renal failure accounts 
for 8% of deaths 10 years following transplantation (5).
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Functional status 
Heart transplantation enables most of the patients with 
previous terminal HF to get back to a normal life. Three 
years after transplantation, ca. 75% of patients are not limited 
in their daily activities and live with no or only minimal 
symptoms, as indicated by a Karnofsky-Index of >90% (5). 
Five years after transplantation, 45% of patients, who 
are in working age, work at least part time (5). Exercise 
capacity after transplantation, as objectively measured by 
peak oxygen uptake, can reach values comparable to those 
of healthy individuals, particularly after a specified training 
program (12).
Summary
Heart transplantation currently remains the treatment of 
choice for patient with severely advanced HF. No other 
treatment option, such as medical therapy or electrical 
and mechanical devices, can compete with the excellent 
results, particularly over the long-term. However, rejection 
and the consequences of immunosuppressive therapy still 
constitute an unsolved problem which limit the success of 
heart transplantation. Mechanical circulatory support with 
modern devices appears to become an important contender 
with the potential to replace heart transplantation, at least in 
selected patients. For this to occur, however, mid- and long-
term survival rates as well as data on functional outcome 
and quality of life have to become available which show 
that the results with mechanical devices are comparable or 
better than those after heart transplantation. A prerequisite 
for such outcome will be the further advancement of 
device technology with respect to biocompatibility and 
transcutaneous energy transfer.
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